

Regarding Item 5

Elections to the Supervisory Board

The terms of office of Supervisory Board Deputy Chair Dr. Anna C. Eichhorn and of Supervisory Board member Mr. Stephen Catling are to end as of the conclusion of the AGM on 18 March 2025. For this reason new elections by the AGM are required to fill these Supervisory Board positions.

Pursuant to Section 96 (1) of the German Stock Corporation Act (AktG), the Company's Supervisory Board consists of the shareholders' Supervisory Board members, and pursuant to Section 95 AktG and Section 9 (1) of the Company's bylaws, it consists of six members elected by the AGM. The AGM is not tied to nominations.

Pursuant to the recommendation of its Audit Committee, the Supervisory Board proposes electing

- a) Dr. Anna C. Eichhorn, Frankfurt am Main, CEO of humatrix AG,
- b) Mr. Stephen Catling, Cambridge, United Kingdom, Managing Director of SJ Catling Ltd.,

as members of the Company's Supervisory Board with effect as of the conclusion of the AGM on 18 March 2025 until the end of the AGM that ratifies the actions of the Supervisory Board for the fiscal year from 1 October 2027 to 30 September 2028.

It is intended that Dr. Anna C. Eichhorn be nominated as a candidate for the position of Deputy Chair of the Supervisory Board if she is elected.

It is intended that the Supervisory Board elections will be implemented as individual elections.

The nominations take into consideration the targets that the Supervisory Board has approved for its composition, and aim to satisfy the competency profile developed for the plenary board. The targets and the competency profile are published in the corporate governance declaration for the 2023/24 fiscal year, which are included in the 2023/24 annual report and which form part of the documents submitted in relation to agenda item 1.

To a large extent, all of the proposed candidates possess the experience and expertise required to exercise the Supervisory Board mandate, as well as the necessary sector, specialist, and corporate knowledge. All of the candidates are familiar both with the business area in which the Company operates and with the capital market environment. The Supervisory Board has satisfied itself that the candidates can devote the expected requisite amount of time to the mandate.

The Supervisory Board will propose a candidate to fill the vacancy left by Prof. Dr. Treffenfeldt, who held the position until the beginning of the financial year, in due course.

Supplementary disclosures and information about the proposed candidates, especially information pursuant to Section 125 (1) Sentence 5 AktG, the candidates' CVs as well as further information relating to the recommendations of the German Corporate Governance Code are reproduced in Section B of this invitation and can also be viewed on the Company's website at

<https://www.brain-biotech-group.com/en/investors/annual-general-meeting/>